Prognostic value of IL6 in young adults presenting with acute coronary syndrome

Mowafy, Ahmed; El-Akabawy, Hazem; Hussein, Ashraf; Hay, Ahmed Abd El

doi:10.1016/j.ehj.2014.01.001

Cited by 6 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that young age of patients, low percentage of smokers, normalized lipid profile, fasting glucose level, and blood pressure are some of the causes for IL-6 concentrations in our CAD group. It was shown that IL-6 is an indicator of the severity of atherosclerotic disease [1,9,14,15,23] and myocardial damage during acute coronary syndrome [24]. Mowafy et al [9] emphasized that IL-6 level positively correlates with severity of the clinical condition and number of affected vessels in patients with acute coronary syndrome.…”

Section: Discussionmentioning

confidence: 99%

“…Molecular mechanisms underlying inflammation-associated diseases include changes of immune response and normal cell microenvironment resulting from an imbalance of inflammatory cytokines [6]. Inflammatory markers are important mediators in the multi-step cascade of atherosclerosis, which finally leads to the rupture of the atherosclerotic plaque [9].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

et al. 2019

View full text Add to dashboard Cite

Background: Over the last two decades, many studies have investigated the association between interleukin 6 (IL-6) and pathogenesis and progression of coronary artery disease (CAD). Patients with CAD manifested at a young age are a particularly interesting group. They differ from older patients, not only in terms of the severity of coronary artery atherosclerosis, but also risk factor profiles, short- and long-term prognosis after myocardial infarction (MI). The role of IL-6 in younger patients with CAD is less well-known. Therefore, our study aimed to analyze the relationship between IL-6 level and other inflammations, atherosclerosis, and cardiac function parameters in early onset CAD patients. Methods: The study covered 100 patients with early onset CAD and a group of 50 healthy participants. Plasma levels of IL-6 and basic biochemical parameters, anthropometric, echocardiographic, and arteries Doppler ultrasound measurements were performed. Results: We did not observe a significant difference in IL-6 concentration in plasma between patients with early onset CAD and a control group, but IL-6 level was negatively correlated with echocardiographic measurements of ascending aorta diameter, left ventricular shortening fraction, and right ventricular end-diastolic diameter in our patients. Conclusions: In patients with early onset CAD, plasma IL-6 level is associated with other inflammation parameters and with cardiac function, potentially contributing to right ventricular remodeling and left ventricular systolic dysfunction. This suggests possible prognostic benefits of long-time observation of IL-6 level after the acute coronary syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The results of a meta-analysis also demonstrated a significant relationship between hs-CRP level and risk of ISR after successful coronary stenting (16). IL-6 is also one of the inflammatory markers that promote atherosclerosis development and plaque rupture (17). After MI, especially STEMI, patients tended to experience a rise in hs-CRP and IL-6 plasma levels that contributed to poor prognosis (50).…”

Section: The Effect Of Q10 Plus Lc Supplementationmentioning

confidence: 99%

“…In spite of heterogeneity across studies, evidence has indicated that plasma high-sensitivity C-reactive protein (hs-CRP) level, as an inflammatory biomarker, could predict coronary ISR after stenting at both admission and follow-up in patients (14)(15)(16). Interleukin-6 (IL-6), as an established inflammatory biomarker of atherosclerosis, could also predict coronary stenosis with high sensitivity and specificity (17,18). Therefore, it is necessary to control inflammation to promote PCI outcomes.…”

Section: Introductionmentioning

confidence: 99%

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Sharifi

Eftekhari

Ostovan

et al. 2017

Iran Red Crescent Med J

View full text Add to dashboard Cite

Background: Following Myocardial Infarction (MI) and percutaneous coronary intervention (PCI), the modification of cardiovascular risk factors and inflammation can improve MI progression and PCI outcomes. Up to now, no certain conclusions have been drawn regarding the effect of therapeutic lifestyle change (TLC) diet and a combination of Q10 plus L-carnitine (LC) supplementation on inflammatory biomarkers of In-Stent Restenosis (ISR), lipid profile, and Left ventricular ejection fraction (LVEF).Objectives: This study aimed to evaluate the effects of TLC diet and Q10 plus LC supplementation on inflammatory biomarkers of ISR, lipid profile, and LVEF following MI and PCI.Methods: This single-blind randomized controlled trial was conducted on 128 subjects. After randomization for treatment allocation, the subjects were divided into the study groups through block randomization. The MI patients were admitted to 2 hospitals, namely Al-Zahra and Kowsar (Shiraz, Iran), between April 2015 and May 2016. The patients were divided into 4 groups receiving TLC diet (A), oral Q10 150 mg/d and LC 1200 mg/d (B), a combination of LC plus Q10 and TLC diet (C), and the routine care (D). This study evaluated Interleukin-6 (IL-6) and high sensitive C-reactive protein (hs-CRP) as inflammatory biomarkers of ISR, lipid profile, and LVEF in 128 patients with MI undergoing PCI before and 3 months after the intervention. Results:The results showed a significant decrease in hs-CRP in groups B (11.8 ± 4.3 to 2.0 ± 1 mg/L) and C (11.7±3.9 to 1.3±1.1 mg/L) (P < 0.0001 and P < 0.0001, respectively), but not in group A. Also, a significant reduction was found in IL-6 in groups A (38.0 ± 15 to 9.4 ± 2 pg/mL), B (34.6 ± 12 to 5.1 ± 2.4 pg/mL), and C (33.7 ± 12 to 4.8 ± 2.1 pg/mL) (P < 0.0001, P < 0.0001, and P < 0.0001, respectively). Additionally, LDL and total cholesterol, but not TG, levels significantly decreased in groups A (150 ± 17 to 80 ± 13 mg/dL), B (148 ± 15 to 77.2 ± 14 mg/dL), and C (142 ± 11 to 64.8 ± 10 mg/dL) (P < 0.0001, P < 0.001, and P < 0.0001, respectively). Nevertheless, only group C showed a significant improvement in LVEF (45.1 ± 8 to 53.6 ± 8) (P < 0.027).Conclusions: An adjuvant therapy with TLC diet and supplementation with Q10 and LC seems to be required for secondary prevention following MI and PCI. TLC diet and Q10 plus LC appeared to be effective in inflammatory biomarkers of ISR as well as LDL reduction.

show abstract

“…9 Increased level of interleukin-6 was seen in acute myocardial infarction, coronary syndrome, unstable angina patients, acute and in advanced heart failure patients. 4,5,[9][10][11][12][13][14][15][16][17][18] Until now C reactive protein is the only established inflammatory marker by World Health Organization standard for coronary risk. 19 Therefore, authors hypothesized that this interleukin-6 can not only serve as new marker for diagnosis of heart failure but also can be used for identification of high risk heart failure patients.…”

Section: Introductionmentioning

confidence: 99%

Role of serum interleukin-6 in heart failure

Deokar¹,

Dandekar²,

Shinde³

et al. 2018

Int J Adv Med

View full text Add to dashboard Cite

Background: A growing body of evidence suggests that inflammation plays the key role in different cardiovascular diseases. But very study has been done so far in relation to serum interleukin-6 in heart failure patients. The aim of the study was to measure serum interleukin-6 in heart failure patients.Methods: Total 22 heart failure patients and 22 age and sex matched controls were included in this study from August 2015 to June 2016 for serum analysis of interleukin-6.Results: serum interleukin-6 was significantly [median(IQR) 14.3(26.2) pg/mL] increased in heart failure patients compared to age and sex matched controls [median(IQR) 0(2.4) pg/mL].Conclusions: Even though little is known about function of interleukin-6 in heart failure patients, this study shows that increased level of IL-6 in heart failure patients plays an important role as a pro-inflammatory marker in development of cardiovascular disease i.e. heart failure.

show abstract

Prognostic value of IL6 in young adults presenting with acute coronary syndrome

Cited by 6 publications

References 26 publications

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

Associations between IL-6 and Echo-Parameters in Patients with Early Onset Coronary Artery Disease

Effects of Therapeutic Lifestyle Change Diet and Q10 Plus L-Carnitine Supplementation on Inflammatory Biomarkers of In-Stent Restenosis, Lipid Profile, and Left Ventricular Ejection Fraction in Myocardial Infarction: A Randomized Clinical Trial

Role of serum interleukin-6 in heart failure

Contact Info

Product

Resources

About